When a gout flare occurs in a patient with severely reduced kidney function, the usual first-line anti-inflammatory options cannot be used safely. This scenario requires a specific, evidence-based protocol tailored to the constraints imposed by an eGFR below 30 mL/min.
Acute gout flare in a patient with severe renal impairment (eGFR <30 mL/min). At this level of kidney dysfunction, clearance of several conventional anti-inflammatory agents is substantially impaired, and their safe use has not been established — restricting the treatment options available.
The recommended approach in this setting is corticosteroid-based, delivered either systemically or directly into the affected joint. Colchicine and NSAIDs should be avoided. The complete protocol — including the preferred modality, sequencing, and specific considerations — is detailed in the full regimen.
Resolution of the acute gout flare with relief of joint pain and inflammation, initiated as early as possible after flare onset.
DOI: 10.1136/annrheumdis-2016-209707
Colchicine and NSAIDs should be avoided in patients with severe renal impairment.
The safe use of colchicine in patients with severe renal impairment (GFR <30 mL/min) has not been established.
Because colchicine clearance is decreased in patients with severe renal impairment, the group considered that it should be avoided in these patients, because a reduced dosage might be a source of therapeutic misuse.
Acute flares of gout should be treated as early as possible.
View source ↗